Quality of life in adults with facial port-wine stains - 18/04/17
Abstract |
Background |
Facial port-wine stains (PWS) are considered by some an aesthetic skin problem, yet impact on quality of life (QoL) has not been objectively documented.
Objective |
We sought to (1) characterize the effect of PWS on QoL in adults, (2) to identify the clinical and demographic factors that affect QoL, and (3) to compare our results with QoL studies in other skin conditions.
Methods |
In total, 244 adults with facial PWS completed an online QoL survey, which included the Skindex-29 instrument.
Results |
QoL in adults with facial PWS was diminished, especially from an emotional perspective. Variables associated with reduced QoL in all Skindex-29 subdomains included comorbid depression, limited facial mobility, and presence of other skin conditions. Persons with hypertrophy had more emotional and symptomatic impairment. The composite dermatologic-specific QoL scores were similar to those of cutaneous T-cell lymphoma, rosacea, alopecia, and vitiligo.
Limitations |
Selection bias was a potential limitation, as participants were primarily recruited from patient support groups.
Conclusion |
Our analysis demonstrates that the presence of a facial PWS has a significant negative impact on QoL. Dermatologists caring for patients with PWS should inquire about QoL, provide appropriate support and resources, and consider QoL when discussing treatment options and obtaining authorization for these procedures.
Le texte complet de cet article est disponible en PDF.Key words : port-wine stain, quality of life, Skindex-29, Sturge-Weber Syndrome, Klippel-Trenaunay Syndrome
Abbreviations used : PWS, QoL, TBSA
Plan
Funding source: Research was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114. |
|
Conflicts of interest: Dr Kristen Kelly received research support from the Sturge-Weber Foundation and the NIH (HD065536); research funding from the Sturge-Weber Foundation; equipment to perform research from Candela-Synderon, Light Sciences Oncology, and Novartis; and consultant fees from MundiPharma. Dr Dorota Korta, Solveig Hagen, and Katherine Grey have nothing to disclose. |
Vol 76 - N° 4
P. 695-702 - avril 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?